{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:06:58Z","timestamp":1794002818902,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41409-020-01124-6","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T01:02:43Z","timestamp":1605315763000},"page":"769-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-229X","authenticated-orcid":false,"given":"Javier","family":"Marco-Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez-Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-8191","authenticated-orcid":false,"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-7494","authenticated-orcid":false,"given":"Pilar","family":"Solves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"key":"1124_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21307\/immunohematology-2019-418","volume":"20","author":"F Yamamoto","year":"2004","unstructured":"Yamamoto F. Review: ABO blood group system-ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes. Immunohematology. 2004;20:3\u201322.","journal-title":"Immunohematology."},{"key":"1124_CR2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","volume":"19","author":"GS Booth","year":"2013","unstructured":"Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1152\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/bmt.2011.135","volume":"46","author":"SD Rowley","year":"2011","unstructured":"Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167\u201385.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bbmt.2010.03.021","volume":"16","author":"N Blin","year":"2010","unstructured":"Blin N, Traineau R, Houssin S, de Latour RP, Petropoulou A, Robin M, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16:1315\u201323.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2017.02.009","volume":"23","author":"S Damodar","year":"2017","unstructured":"Damodar S, Shanley R, MacMillan M, Ustun C, Weisdorf D. Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source. Biol Blood Marrow Transplant. 2017;23:795\u2013804.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1046\/j.1537-2995.2003.00465.x","volume":"43","author":"N Worel","year":"2003","unstructured":"Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion. 2003;43:1153\u201361.","journal-title":"Transfusion."},{"key":"1124_CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0887-7963(87)70009-1","volume":"1","author":"LD Petz","year":"1987","unstructured":"Petz LD. Immunohematologic problems associated with bone marrow transplantation. Transfus Med Rev. 1987;1:85\u2013100.","journal-title":"Transfus Med Rev"},{"key":"1124_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V75.1.290.290","volume":"75","author":"JP Gm\u00fcr","year":"1990","unstructured":"Gm\u00fcr JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood. 1990;75:290\u20135.","journal-title":"Blood."},{"key":"1124_CR9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.V98.6.1687","volume":"98","author":"CD Bolan","year":"2001","unstructured":"Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687\u201394.","journal-title":"Blood."},{"key":"1124_CR10","doi-asserted-by":"crossref","unstructured":"Aneke JC, Sondi N, Thyagu S, Cserti-Gazdewich CM, Pendergrast J. Donor-specific isoagglutinin clearance in ABO mismatched stem cell transplant recipients: how long should it normally take?. Blood. 2018;132 Suppl 1:1260\u20130.","DOI":"10.1182\/blood-2018-99-115075"},{"key":"1124_CR11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1365-2141.2003.04128.x","volume":"120","author":"J-H Lee","year":"2003","unstructured":"Lee J-H, Lee J-H, Choi S-J, Kim S, Seol M, Kwon S-W, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol. 2003;120:702\u201310.","journal-title":"Br J Haematol"},{"key":"1124_CR12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2141.2005.05364.x","volume":"128","author":"LM Griffith","year":"2005","unstructured":"Griffith LM, McCoy JPJ, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128:668\u201375.","journal-title":"Br J Haematol"},{"key":"1124_CR13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00000441-199112000-00009","volume":"302","author":"EA Sahovic","year":"1991","unstructured":"Sahovic EA, Flick J, Graham CD, Stuart RK. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991;302:369\u201373.","journal-title":"Am J Med Sci"},{"key":"1124_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-007-0304-8","volume":"86","author":"G Helbig","year":"2007","unstructured":"Helbig G, Stella-Holowiecka B, Wojnar J, Krawczyk M, Krzemien S, Wojciechowska-Sadus M, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol. 2007;86:677\u201383.","journal-title":"Ann Hematol"},{"key":"1124_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bmt.1702121","volume":"25","author":"J-H Lee","year":"2000","unstructured":"Lee J-H, Lee K-H, Kim S, Lee J-S, Kim SH, Kwon S-W, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:179\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V96.3.1150","volume":"96","author":"M Mielcarek","year":"2000","unstructured":"Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 2000;96:1150\u20136.","journal-title":"Blood."},{"key":"1124_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330601111540","volume":"12","author":"K-E Zhu","year":"2007","unstructured":"Zhu K-E, Li J-P, Zhang T, Zhong J, Chen J. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology. 2007;12:117\u201321.","journal-title":"Hematology."},{"key":"1124_CR18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.12210","volume":"160","author":"FM Aung","year":"2013","unstructured":"Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160:798\u2013805.","journal-title":"Br J Haematol"},{"key":"1124_CR19","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2019-131118","volume":"134","author":"P Mehta","year":"2019","unstructured":"Mehta P, Ramprakash S, Raghuram C, Trivedi D, Marwah P, Soni R, et al. In-vivo adsorption of iso-haemagglutinin (IHA) antibodies by donor type red cell transfusion during conditioning is a safe and effective method to overcome major ABO incompatibility-related acute hemolytic reactions in stem cell transplant using bone marrow as stem cell graft source. Blood. 2019;134:4467\u20137.","journal-title":"Blood."},{"key":"1124_CR20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.13356","volume":"94","author":"G Stussi","year":"2009","unstructured":"Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gm\u00fcr J, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009;94:239\u201348.","journal-title":"Haematologica"},{"key":"1124_CR21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V77.4.906.906","volume":"77","author":"A Heyll","year":"1991","unstructured":"Heyll A, Aul C, Runde V, Arning M, Schneider W, Wernet P. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin. Blood. 1991;77:906.","journal-title":"Blood."},{"key":"1124_CR22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1607-551X(09)70096-8","volume":"20","author":"H-J Tsai","year":"2004","unstructured":"Tsai H-J, Lin S-F, Liu T-C, Chang C-S, Hsiao H-H, Chen T-P. Pure red cell aplasia after ABO major-mismatched allogeneic peripheral blood stem cell transplantation successfully treated with plasma exchange and low-dose steroid: two case reports. Kaohsiung J Med Sci. 2004;20:128\u201332.","journal-title":"Kaohsiung J Med Sci"},{"key":"1124_CR23","first-page":"471","volume":"10","author":"B Labar","year":"1992","unstructured":"Labar B, Bogdani\u0107 V, Nemet D, Kovacevi\u0107-Metelko J, Mrsi\u0107 M, Pavleti\u0107 Z, et al. Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. Bone Marrow Transplant. 1992;10:471\u20132.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.0041-1132.2005.00445.x","volume":"45","author":"F Sor\u00e0","year":"2005","unstructured":"Sor\u00e0 F, De Matteis S, Piccirillo N, Chiusolo P, Laurenti L, Putzulu R, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion. 2005;45:643\u20135.","journal-title":"Transfusion."},{"key":"1124_CR25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbmt.2013.04.004","volume":"19","author":"M Hirokawa","year":"2013","unstructured":"Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19:1026\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR26","first-page":"397","volume":"16","author":"G Tomac","year":"2018","unstructured":"Tomac G, Bojanic I, Mazic S, Vidovic I, Raos M, Cepullic BG, et al. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation. Blood Transfus. 2018;16:397\u2013404.","journal-title":"Blood Transfus"},{"key":"1124_CR27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2018.04.022","volume":"24","author":"A Busca","year":"2018","unstructured":"Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:1765\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bbmt.2016.02.008","volume":"22","author":"FM Aung","year":"2016","unstructured":"Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, et al. Pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplantation is associated with severe pancytopenia. Biol Blood Marrow Transplant. 2016;22:961\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1124_CR29","doi-asserted-by":"crossref","unstructured":"Atilla E, Topcuoglu P, Akkus E, Ataca Atilla P, Civriz Bozdag S, Kurt Yuksel M, et al. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients. Blood. 2018;132 Suppl 1:3472\u20132.","DOI":"10.1182\/blood-2018-99-118314"},{"key":"1124_CR30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.2002.03905.x","volume":"119","author":"J Maciej Zaucha","year":"2002","unstructured":"Maciej Zaucha J, Mielcarek M, Takatu A, Little M-T, Gooley T, Baker J, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol. 2002;119:740\u201350.","journal-title":"Br J Haematol"},{"key":"1124_CR31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00007890-198803000-00005","volume":"45","author":"IJ Sniecinski","year":"1988","unstructured":"Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation. 1988;45:530\u20134.","journal-title":"Transplantation."},{"key":"1124_CR32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1537-2995.1993.33593255604.x","volume":"33","author":"O Paltiel","year":"1993","unstructured":"Paltiel O, Cournoyer D, Rybka W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion. 1993;33:418\u201321.","journal-title":"Transfusion."},{"key":"1124_CR33","first-page":"335","volume":"13","author":"K Ohashi","year":"1994","unstructured":"Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone marrow transplantation team. Bone Marrow Transplant. 1994;13:335\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bmt.1701012","volume":"20","author":"A Santamar\u00eda","year":"1997","unstructured":"Santamar\u00eda A, Sureda A, Martino R, Domingo-Alb\u00f3s A, Mu\u00f1iz-D\u00edaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant. 1997;20:1105\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1046\/j.1365-2141.1999.1331d.x","volume":"104","author":"P Bavaro","year":"1999","unstructured":"Bavaro P, Di Girolamo G, Olioso P, Papalinetti G, Iacone A, Accorsi P, et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol. 1999;104:930\u20131.","journal-title":"Br J Haematol"},{"key":"1124_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1703699","volume":"30","author":"M Yamaguchi","year":"2002","unstructured":"Yamaguchi M, Sakai K, Murata R, Ueda M. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:539\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1537-2995.2002.00027.x","volume":"42","author":"A Badros","year":"2002","unstructured":"Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002;42:205\u20139.","journal-title":"Transfusion."},{"key":"1124_CR38","first-page":"61","volume":"10","author":"K-E Zhu","year":"2002","unstructured":"Zhu K-E, Xu Y, Wu D, Zhong J. Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002;10:61\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"1124_CR39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-3148.2012.01156.x","volume":"22","author":"W Zhidong","year":"2012","unstructured":"Zhidong W, Hongmin Y, Hengxiang W. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med. 2012;22:302\u20134.","journal-title":"Transfus Med"},{"key":"1124_CR40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2169\/internalmedicine.36.487","volume":"36","author":"S Ohta","year":"1997","unstructured":"Ohta S, Yokoyama H, Ise T, Takasawa K, Wada T, Nakao S, et al. Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation. Intern Med. 1997;36:487\u201391.","journal-title":"Intern Med"},{"key":"1124_CR41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1537-2995.2000.40050543.x","volume":"40","author":"N Worel","year":"2000","unstructured":"Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Kn\u00f6bl P, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40:543\u201350.","journal-title":"Transfusion."},{"key":"1124_CR42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1537-2995.1995.35795357883.x","volume":"35","author":"W Nussbaumer","year":"1995","unstructured":"Nussbaumer W, Schwaighofer H, Gratwohl A, Kilga S, Schonitzer D, Nachbaur D, et al. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion. 1995;35:592\u20135.","journal-title":"Transfusion."},{"key":"1124_CR43","first-page":"99","volume":"4","author":"R Or","year":"1991","unstructured":"Or R, Naparstek E, Mani N, Slavin S. Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Two case reports with successful response to plasmapheresis. Transpl Int. 1991;4:99\u2013102.","journal-title":"Transpl Int"},{"key":"1124_CR44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1526-0968.1999.00135.x","volume":"3","author":"C Ust\u00fcn","year":"1999","unstructured":"Ust\u00fcn C, Celebi H, Arat M, Ozcan M, Dilek I, G\u00fcrman G, et al. Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: a case report. Ther Apher. 1999;3:275\u20137.","journal-title":"Ther Apher"},{"key":"1124_CR45","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1111\/trf.13269","volume":"55","author":"CM Dellacasa","year":"2015","unstructured":"Dellacasa CM, D\u2019Ardia S, Allione B, Aydin S, Tassi V, Francisci T, et al. Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation. Transfusion. 2015;55:2979\u201382.","journal-title":"Transfusion."},{"key":"1124_CR46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jca.21553","volume":"33","author":"K Sackett","year":"2018","unstructured":"Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher. 2018;33:108\u201312.","journal-title":"J Clin Apher"},{"key":"1124_CR47","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/ndt\/gfg364","volume":"18","author":"W Rabitsch","year":"2003","unstructured":"Rabitsch W, Kn\u00f6bl P, Greinix H, Prinz E, Kalhs P, H\u00f6rl WH, et al. Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2003;18:2405\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1124_CR48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00320.x","volume":"73","author":"F Verholen","year":"2004","unstructured":"Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol. 2004;73:441\u20136.","journal-title":"Eur J Haematol"},{"key":"1124_CR49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/10245330410001714202","volume":"10","author":"K Zhu","year":"2005","unstructured":"Zhu K, Chen J, Chen S. Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology. 2005;10:365\u201370.","journal-title":"Hematology."},{"key":"1124_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-008-0599-0","volume":"88","author":"B Fang","year":"2009","unstructured":"Fang B, Song Y, Li N, Li J, Han Q, Zhao RC. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol. 2009;88:261\u20136.","journal-title":"Ann Hematol"},{"key":"1124_CR51","first-page":"471","volume":"16","author":"DF Roychowdhury","year":"1995","unstructured":"Roychowdhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant. 1995;16:471\u20132.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR52","first-page":"1279","volume":"36","author":"H Furuya","year":"1995","unstructured":"Furuya H, Wakayama T, Tanaka J, Tsumori M, Hatazoe T, Ohguni S, et al. Treatment with bolus methylprednisolone for pure red cell aplasia after ABO incompatible bone marrow transplantation in a patient with chronic myelocytic leukemia. Rinsho Ketsueki. 1995;36:1279\u201383.","journal-title":"Rinsho Ketsueki"},{"key":"1124_CR53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002770000275","volume":"80","author":"M-H Yang","year":"2001","unstructured":"Yang M-H, Hsu H-C. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. Ann Hematol. 2001;80:299\u2013301.","journal-title":"Ann Hematol"},{"key":"1124_CR54","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.bmt.1705378","volume":"37","author":"UR Deotare","year":"2006","unstructured":"Deotare UR, Vishwabandya A, Mathews V, George B, Srivastava A, Chandy M. Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:1149\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR55","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/tme.12143","volume":"24","author":"X Yang","year":"2014","unstructured":"Yang X, Levis M. Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation. Transfus Med. 2014;24:246\u20138.","journal-title":"Transfus Med"},{"key":"1124_CR56","first-page":"760","volume":"57","author":"Y Hiroshima","year":"2016","unstructured":"Hiroshima Y, Shiono Y, Suzuki I, Yamamoto M, Kato Y, Tajima K, et al. Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation. Rinsho Ketsueki. 2016;57:760\u20134.","journal-title":"Rinsho Ketsueki"},{"key":"1124_CR57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.hemonc.2017.08.004","volume":"11","author":"R Varela G\u00f3mez","year":"2018","unstructured":"Varela G\u00f3mez R, V\u00e1zquez V\u00e1zquez G, Noriega Concepci\u00f3n V, Galego Garc\u00eda A, And\u00f3n Saavedra C. Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2018;11:44\u20136.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1124_CR58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1703668","volume":"30","author":"AA Maschan","year":"2002","unstructured":"Maschan AA, Skorobogatova EV, Balashov DN, Pashanov ED, Trakhtman PE, Schipitzina IP, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant. 2002;30:405\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR59","first-page":"437B","volume":"102","author":"H Al-Okk","year":"2003","unstructured":"Al-Okk H, Diaz B, Stives S, Parumog N, Conway M, Nath R. Successful resolution of pure red cell aplasia (PRCA) following major ABO incompatible unrelated donor stem cell transplantation using rituximab. Blood. 2003;102:437B\u20138B.","journal-title":"Blood"},{"key":"1124_CR60","first-page":"ECR33","volume":"90","author":"G Helbig","year":"2005","unstructured":"Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica. 2005;90:ECR33.","journal-title":"Haematologica."},{"key":"1124_CR61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0609.2005.00582.x","volume":"76","author":"H-Y Woo","year":"2006","unstructured":"Woo H-Y, Min C-K, Lee S-M, Cho H-S, Kim S-Y, Lee S, et al. Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion. Eur J Haematol. 2006;76:160\u20133.","journal-title":"Eur J Haematol"},{"key":"1124_CR62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199309148522","volume":"9","author":"PJ Bierman","year":"1993","unstructured":"Bierman PJ, Warkentin P, Hutchins MR, Klassen LW. Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk Lymphoma. 1993;9:169\u201371.","journal-title":"Leuk Lymphoma"},{"key":"1124_CR63","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02984003","volume":"86","author":"Y Ebihara","year":"2007","unstructured":"Ebihara Y, Manabe A, Tsuruta T, Ishikawa K, Hasegawa D, Ohtsuka Y, et al. The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann syndrome. Int J Hematol. 2007;86:446\u201350.","journal-title":"Int J Hematol"},{"key":"1124_CR64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1701384","volume":"22","author":"C Selleri","year":"1998","unstructured":"Selleri C, Raiola A, De Rosa G, Luciano L, Pezzullo L, Picardi M, et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant. 1998;22:605\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR65","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367\u201372.","journal-title":"Blood."},{"key":"1124_CR66","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.20932","volume":"82","author":"B Fang","year":"2007","unstructured":"Fang B, Song Y, Zhao RC, Han Q, Cao Y. Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol. 2007;82:772\u20133.","journal-title":"Am J Hematol"},{"key":"1124_CR67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D. 2019;19:73\u201392.","journal-title":"Drugs R D."},{"key":"1124_CR68","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/bmt.2011.176","volume":"47","author":"L-M Poon","year":"2012","unstructured":"Poon L-M, Koh LP. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant. 2012;47:870\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tme.12121","volume":"24","author":"F Khan","year":"2014","unstructured":"Khan F, Linden MA, Zantek ND, Vercellotti GM. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation. Transfus Med. 2014;24:187\u20138.","journal-title":"Transfus Med"},{"key":"1124_CR70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/tme.12216","volume":"25","author":"JL Shahan","year":"2015","unstructured":"Shahan JL, Hildebrandt GC. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med. 2015;25:342\u20134.","journal-title":"Transfus Med"},{"key":"1124_CR71","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.25515","volume":"94","author":"S Bathini","year":"2019","unstructured":"Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019;94:E216\u20139.","journal-title":"Am J Hematol"},{"key":"1124_CR72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13343","volume":"104","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 2020;104:145\u20137.","journal-title":"Eur J Haematol"},{"key":"1124_CR73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.seminhematol.2014.10.002","volume":"52","author":"R Desmond","year":"2015","unstructured":"Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol. 2015;52:31\u20137.","journal-title":"Semin Hematol"},{"key":"1124_CR74","doi-asserted-by":"crossref","first-page":"6084012","DOI":"10.1155\/2019\/6084012","volume":"2019","author":"H Nishida","year":"2019","unstructured":"Nishida H, Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. J Oncol. 2019;2019:6084012.","journal-title":"J Oncol"},{"key":"1124_CR75","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","volume":"379","author":"CI Chapuy","year":"2018","unstructured":"Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379:1846\u201350.","journal-title":"N Engl J Med"},{"key":"1124_CR76","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","volume":"55","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Kaivers J, Germing U, Haas R, Ackerstaff S, Hoffmann T, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55:1191\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"1124_CR77","doi-asserted-by":"crossref","unstructured":"Jeyaraman P, Borah P, Rajput P, Dayal N, Pathak S, Naithani R. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis. 2020;102464.","DOI":"10.1016\/j.bcmd.2020.102464"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01124-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01124-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01124-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:16:57Z","timestamp":1684617417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01124-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01124-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,14]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}